The key opportunities for the pharmaceutical industry in the developing world are to be found in Brazil, China, India, Vietnam, North Africa, Turkey and potentially some of the eastern European states, according to Health-care in the Developing World, a new study published by Financial Times Management Reports.
However, notes author Tom Raggett, all these countries still present problems. Whether to establish manufacturing facilities, enter the market through a joint venture or opt for third-party representation are all questions which companies will need to answer to their own satisfaction in each market.
The report focuses on the markets of Asia, Latin America and the Middle East, because they share similarities which the rest of the developing world does not. These markets are attractive to multinationals because of their high rates of Gross Domestic Product growth compared to the developed world, and their large and growing number of potential consumers. However, these countries frequently still have strong government regulation of their economies, and extreme infrastructural problems, making advertising, distribution and manufacturing difficult.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze